Literature DB >> 25365090

RADAI-5 to monitor rheumatoid arthritis.

B F Leeb1, P M Haindl, H P Brezinschek, T Nothnagl, B Rintelen.   

Abstract

Providing the physician with sufficient information about the disease course can be regarded as the most important requirement for any disease assessment tool besides easy applicability and time-sparing documentation. Applying the RADAI-5 in daily routine provides the patient's view at any time completing the questionnaire. In a first study, the RADAI-5 resulted to be highly significantly correlated to the RADAI, and all composite indexes. Changes of the RADAI-5, the DAS28-ESR, and the CDAI were significantly correlated, indicating the instrument's sensitivity to change. A second study including 392 RA patients led to the establishment of thresholds for disease activity categories according to the RADAI-5, as follows: 0.0 up to 1.4 for a remission-like state, 1.6 up to 3.0 for mild disease activity, 3.2 up to 5.4 for moderate and from 5.6 up to 10.0 for high disease activity. In a third study, remission according to the RADAI-5 appeared to be highly specific for the ACR/EULAR criteria for remission The RADAI-5 questionnaire constitutes an easily applicable tool for routine RA monitoring, providing physicians with reliable information about the disease course and sensitivity enough to sound the alarm should complications occur.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25365090

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  Serum C-Reactive Protein/Albumin Ratio in Rheumatoid Arthritis and its Relationship With Disease Activity, Physical Function, and Quality of Life.

Authors:  İsmihan Sunar; Şebnem Ataman
Journal:  Arch Rheumatol       Date:  2020-02-07       Impact factor: 1.472

2.  Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA).

Authors:  Burkhard F Leeb; Pia M Haindl; Hans-Peter Brezinschek; Harsono T H Mai; Christoph Deutsch; Bernhard Rintelen
Journal:  BMC Musculoskelet Disord       Date:  2015-04-01       Impact factor: 2.362

3.  Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction.

Authors:  Yomei Shaw; Delphine S Courvoisier; Almut Scherer; Adrian Ciurea; Thomas Lehmann; Veronika K Jaeger; Ulrich A Walker; Axel Finckh
Journal:  RMD Open       Date:  2021-04

4.  The effect on work presenteeism of job retention vocational rehabilitation compared to a written self-help work advice pack for employed people with inflammatory arthritis: protocol for a multi-centre randomised controlled trial (the WORKWELL trial).

Authors:  Alison Hammond; Chris Sutton; Sarah Cotterill; Sarah Woodbridge; Rachel O'Brien; Kate Radford; Denise Forshaw; Suzanne Verstappen; Cheryl Jones; Antonia Marsden; Martin Eden; Yeliz Prior; June Culley; Paula Holland; Karen Walker-Bone; Yvonne Hough; Terence W O'Neill; Angela Ching; Jennifer Parker
Journal:  BMC Musculoskelet Disord       Date:  2020-09-10       Impact factor: 2.362

5.  Treatment of Rheumatoid Arthritis with Certolizumab Pegol: Results from PROACTIVE, a Non-Interventional Study in the UK and Ireland.

Authors:  Namita Kumar; Sophia Naz; Mark Quinn; John Ryan; Thomas Kumke; Tom Sheeran
Journal:  Adv Ther       Date:  2018-08-03       Impact factor: 3.845

6.  Patients' experiences regarding self-monitoring of the disease course: an observational pilot study in patients with inflammatory rheumatic diseases at a rheumatology outpatient clinic in The Netherlands.

Authors:  Lisanne Renskers; Sanne Aa Rongen-van Dartel; Anita Mp Huis; Piet Lcm van Riel
Journal:  BMJ Open       Date:  2020-08-20       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.